Telaglenastat Hydrochloride

DRUG5 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced Lung Non-Small Cell CarcinomaAdvanced Malignant Solid NeoplasmAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, IDH-Mutant, Grade 3Leptomeningeal NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm

Phase 1

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Active, not recruitingNCT03528642

National Cancer Institute (NCI)Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3

Start: 2019-05-01End: 2026-05-08Target: 40Updated: 2026-04-03

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Active, not recruitingNCT03798678

National Cancer Institute (NCI)Recurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2019-07-08End: 2026-06-30Target: 36Updated: 2026-04-03

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Active, not recruitingNCT03831932

National Cancer Institute (NCI)Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

Start: 2020-03-16End: 2027-03-13Updated: 2026-04-03

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Active, not recruitingNCT04250545

National Cancer Institute (NCI)Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain +4

Start: 2020-10-26End: 2026-11-21Updated: 2025-11-25

Phase 2

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Active, not recruitingNCT03872427

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor +1

Start: 2019-12-14End: 2026-04-16Updated: 2025-11-14

Related Papers

Abstract 3261: Improving targeted therapy in female patients with lung squamous cell carcinoma

Cancer Research2024-03-22

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood2022-11-153 citations

CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)

Neuro-Oncology2022-11-014 citations

Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia

Blood2020-11-042 citations

Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Blood2019-11-134 citations

A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642).

Journal of Clinical Oncology2019-05-2017 citations